The Agilent Bravo automated liquid-handling platform and BioSystem Development’s AssayMap technology combine high throughput and best-in-course automated liquid managing with AssayMAP microchromatography technology to enable accurate chromatographic separation with accuracy circulation control. ‘We are worked up about bringing BioSystem Advancement, a valued partner, into Agilent,’ said Fred Strohmeier, vice president and general supervisor of Agilent’s Liquid Phase Analysis Division within the business’s Life Sciences Group. ‘BioSystem Development’s innovative and versatile microchromatography technology, and the team’s applications expertise, will help Agilent expand its capabilities as a sample-prep provider for the full life sciences market.Because the cohort we studied was youthful and more racially diverse than cohorts in previous studies,13,14 we examined for effect modification relating to age .31 In the analysis of SSRIs, we stratified the analysis based on the use of just that drug class versus the use of multiple antidepressant classes. To evaluate the effect of potential misclassification of exposure, we redefined exposure status as having had one or more prescriptions filled through the first trimester ; we redefined the reference group as ladies with no antidepressant exposure throughout being pregnant. To evaluate the result of potential misclassification of final result, we restricted the outcome to inpatient diagnoses only and extended infant follow-up to 1 1 year. We corrected chances ratios for outcome misclassification using sensitivities and specificities consistent with the positive predictive values estimated in the internal validation study.33 Results Characteristics of the Study Cohort We identified 949,504 eligible pregnancies.